By Martin Khor*
PENANG, Malaysia, Dec 2017 (IPS) – The growing crisis of antibiotic resistance is catching the attention of policy makers, but not at a rate enough to tackle it.
More diseases are affected by resistance, meaning the bacteria cannot be killed even if different drugs are used on some patients, who then succumb.
We are staring at a future in which antibiotics don’t work, and many of us or our children will not be saved from TB, cholera, deadly forms of dysentery, and germs contracted during surgery.
The World Health Organisation will discuss a resolution in May at its annual assembly of Health Ministers on microbial resistance, including a global action plan. There have been such resolutions before but little action.
This year may be different, because powerful countries like the United Kingdom are now convinced that years of inaction have caused the problem to fester, until it has grown to mind-boggling proportions.
The UK-based Chatham House held two meetings last October and last month (together with the Geneva Graduate Institute) on this issue, both presided over by the Chief Medical Officer of England, Prof. Dame Sally Davies.
This remarkable woman has taken on antibiotic resistance as a professional and personal campaign. In a recent book, “The drugs don’t work”, she revealed that for her annual health report, she decided in 2012 to focus on infectious diseases.
“I am not easily rattled, but what I learnt scared me, not just as a doctor, but as a mother, a wife and a friend. Our findings were simple: We are losing the battle against infectious diseases. Bacteria are fighting back and are becoming resistant to modern medicine.In short, the drugs don’t work.”
Davies told the meetings that antibiotics add on average 20 years to our lives and that for over 70 years they have enabled us to survive life-threatening infections and operations.
“The truth is, we have been abusing them as patients, as doctors, as travellers, and in our food,” she says in her book.
“No new class of antibacterial has been discovered for 26 years and the bugs are fighting back. In a few decades, we may start dying from the most common place of operations and ailments that can today be treated easily.”
At the two Chatham House meetings, which I attended, different aspects of the crisis and possible actions were discussed. In one of the sessions, I made a summary of the actions needed, including:
More scientific research of how resistance is caused and spread, including the emergence of antibiotic-resistance genes as in the NDM-1 enzyme, whose speciality is to accelerate and spread resistance within and among bacteria.
Surveys in every country to determine the prevalence of resistance to antibiotics in bacteria causing various diseases.
Health guidelines and regulations in every country to guide doctors on when (and when not) to prescribe antibiotics, and instructing patients how to properly use them.
Regulations for drug companies on ethical marketing of their medicines, and on avoiding sales promotion to doctors or the public that leads to over-use.
Educating the public on using antibiotics properly, including when they should not be used.
Ban the use of antibiotics in animals and animal feed for the purpose of inducing growth of the animals (for commercial profit), and restrict the use in animals only for treating ailments.
Promote the development of new antibiotics and in ways (including financing) that do not make the new drugs the exclusive property of drug companies.
Ensure that ordinary and poor people in developing countries also have access to the new medicines, which would otherwise be very expensive, and thus only the very rich can afford to use them.
On the first point, a new and alarming development has been the the discovery of a gene, known as NDM-1, that has the ability to alter bacteria and make them highly resistant to all known drugs.
In 2010, only two types of bacteria were found to be hosting the NDM-1 gene — E Coli and Klebsiella pneumonia.
It was found that the gene can easily jump from one type of bacteria to another. In May 2011, scientists from Cardiff University who had first reported on NDM-1’s existence found that the NDM-1 gene has been jumping among various species of bacteria at a “superfast speed” and that it “has a special quality to jump between species without much of a problem”.
While the gene was found only in E Coli when it was initially detected in 2006, now the scientists had found NDM-1 in more than 20 different species of bacteria. NDM1 can move at an unprecedented speed making more and more species of bacteria drug-resistant.
Also in May 2011, there was an outbreak of a deadly disease caused by a new strain of the E-Coli bacteria that killed more than 20 people and affected another 2,000 in Germany.
Although the “normal” E-coli usually produces mild sickness in the stomach, the new strain of E-Coli 0104 causes bloody diarrhea and severe stomach cramps, and in more serious cases damages blood cells and the kidneys. A major problem is that the bacterium is resistant to antibiotics.
Tuberculosis is a disease making a comeback. In 2011, the WHO found there were half a million new cases of TB in the world that were multidrug resistant (known as MDR-TB), meaning that they could not be treated using most medicines.
And about 9% of multi-drug resistant TB cases also have resistance to two other classes of drugs and are known as extensively drug-resistant TB (XDR-TB). Patients having XDR-TB cannot be treated successfully.
Research has also found that in South-east Asia, strains of malaria are also becoming resistant to treatment.
In 2012, WHO Director General Dr Margaret Chan warned that every anitibiotic ever developed was at risk of becoming useless.
“A post-antibiotic era means in effect an end to modern medicine as we know it. Things as common as strep throat or a child’s scratched knee could once again kill.”
The World Health Assembly in May is an opportunity not to be missed to finally launch a global action plan to address this crisis.
*Martin Khor is Executive Director of the South Centre, a think tank for developing countries, based in Geneva.